Why the study?
Does a novel investigational cTnI assay improve early diagnosis of myocardial infarction in patients with suspected acute coronary syndrome compared to a reference cTnI assay and myoglobin?
Does a novel investigational cTnI assay improve early diagnosis of myocardial infarction in patients with suspected acute coronary syndrome compared to a reference cTnI assay and myoglobin?
A novel cTnI assay significantly improves the early detection of myocardial infarction upon admission compared to standard cTnI and myoglobin assays.
Answers are grounded in this paper and cite their sources.
May support earlier myocardial injury detection in suspected ACS; leaves open whether the assay improves MI diagnosis pending prospective validation.
BACKGROUND: We evaluated the clinical performance of a novel cardiac troponin I (cTnI) assay specifically designed to improve the very early risk stratification in acute coronary syndromes. SUBJECTS AND METHODS: Serum and plasma samples (taken 0, 6-12 h and 24 h after admission) from 531 patients with suspected acute coronary syndrome were studied using a novel investigational cTnI assay, reference cTnI assay and myoglobin. The lowest cTnI concentration giving a total assay imprecision of 10% was used as the positive myocardial infarction (MI) cut-off value. RESULTS: At the time of admission, the investigational assay was positive in 27.9% of the patients, the reference cTnI assay was positive in only 17.5% (P < 0.001) and myoglobin in 24.1% (P = 0.067). Receiver operating characteristic (ROC) curve analysis for the detection of myocardial injury on admission gave area-under-curve (AUC) values of 0.937, 0.775 and 0.762, respectively (P < 0.001). Of those MI patients who presented within 3 h of symptom onset, 50.0% were identified by the investigational assay at the time of presentation, compared with 44.2% by myoglobin (P = 0.791) but only 11.5% by the reference assay (P < 0.001). CONCLUSIONS: The novel cTnI assay considerably improves the performance of cTnI as an early rule-in biomarker for MI.
No takes yet. Share an insight, caveat, or question.
Ilva et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: